| ¿µ¹® | basal layer of skin | ÇÑ±Û | ±âÀúÃþ |
|---|---|---|---|
| ¼³¸í | Ç¥ÇÇÀÇ °¡Àå ¾Æ·¡ ºÎºÐÀÌ¸ç ¼¼Æ÷ÀÇ ¸ð¾çÀÌ ºñ±³Àû Á÷»ç°¢Çü¿¡ °¡±õ°í ÀÏÁ¤ÇÑ ¹è¿À» ÇÑ´Ù. |
||
| ¿µ¹® | skin tag | ÇÑ±Û | ÁãÁ¥, ÇǺο¬¼º¼¶À¯Á¾ |
|---|---|---|---|
| ¼³¸í | ÁÖ·Î ¸ñ, °Üµå¶ûÀÌ, ´Ù¸®¿¡ »ý±â´Â »ì»ö ¶Ç´Â °ú»ö¼Ò Ä§Âø¼ºÀÇ ÀÛÀº ¸ñÀ» °¡Áø ¼¶À¯¼º µ¹Ãâ¹°·Î ´ë°³ ¹«Áõ»óÀÌ´Ù. |
||
| ¿µ¹® | skin | ÇÑ±Û | ÇǺΠ|
|---|---|---|---|
| ¼³¸í | ½Åü¸¦ ½Î°í ÀÖ´Â ¹Ù±ùÃþÀ¸·Î¼ Ç¥ÇÇ, ÁøÇÇ, ÇÇÇÏÁ¶Á÷À¸·Î ±¸¼ºµÇ¸ç, ¿ÜºÎ ȯ°æÀ¸·ÎºÎÅÍ ½Åü¸¦ º¸È£Çϰí ü¿ÂÀ» Á¶ÀýÇÏ´Â ±â´ÉÀ» °¡Áü. 1.Ç¥ÇÇ: ÇǺÎÀÇ °¡Àå ¹Ù±ùÃþÀ¸·Î¼ ¿Ü¹è¿±¿¡¼ ±â¿øÇÏ¸ç °¢ÁúÀ̶ó´Â ±¸Á¶ ´Ü¹éÁúÀ» »ý»êÇÏ´Â ±â´ÉÀ» °¡Áü. 4°¡ÁöÀÇ ¼¼Æ÷°¡ Àִµ¥, °¢Áú¼¼Æ÷, ¸á¶ó´Ñ¼¼Æ÷, Langerhans ¼¼Æ÷, ºÎÁ¤Çü ¼¼Æ÷, Merkel¼¼Æ÷°¡ ÀÖ´Ù. Ç¥ÇÇ¿¡´Â ÀÌ 4°¡Áö ¼¼Æ÷¿Ü¿¡ ´ÙÀ½°ú °°Àº Ç¥ÇÇ ºÎ¼Ó±â°¡ ÀÖ´Ù. ¿¡Å©¸° ¶¡»ù(eccrine sweat gland): Á¡¸· ÇǺΠ°æ°è ºÎÀ§ µî Ư¼öÇÑ ºÎÀ§¸¦ Á¦¿ÜÇÑ ¸ðµç ÇǺο¡¼ ¹ß°ßµÇ¸ç ¶¡À» ºÐºñÇÏ´Â »ùÀ¸·Î¼ ½Åü ¿ Á¶Àý ü°èÀÇ Áß¿äÇÑ ¿ä¼Ò. ¾ÆÆ÷Å©¸°»ù(apocrine gland): °Üµå¶ûÀÌ, Á¥²ÉÆÇ, Ç×¹® »ý½Ä±â ºÎÀ§, ¿ÜÀ̵µ, ´«²¨Ç® µî¿¡¼¸¸ ¹ß°ßµÇ¸ç ºÐºñ¹°ÀÇ ±â´ÉÀº Àß ¾Ë·ÁÁ® ÀÖÁö ¾ÊÀ¸³ª µ¿¹°¿¡¼´Â ¹æ¾î ¹× ¼ºÀû ±â´ÉÀÌ ÀÖÀ½. ÅÐÁÖ¸Ó´Ï(hair follicle): ¼Õ¹Ù´Ú, ¹ß¹Ù´Ú µî Ư¼ö ºÎÀ§¸¦ Á¦¿ÜÇÑ ½Åü Àü ºÎÀ§¿¡ ºÐÆ÷Çϸç Àΰ£¿¡¼ Áß¿äÇÑ »ý¸®Àû ±â´ÉÀº ¾øÀ¸³ª ¼ºÀû ¸Å·ÂÀ» Áö´Ï´Â ½Åü Àå½ÄÀÇ ±â´ÉÀ» °¡Áü. ±â¸§»ù(sebaceous gland): ¼Õ¹Ù´Ú°ú ¹ß¹Ù´ÚÀ» Á¦¿ÜÇÑ Àü ÇǺο¡ ºÐÆ÷ÇÏ¸ç ºÐºñ¹°À» ±â¸§(sebum)¶ó ºÎ¸§. ³²¼º È£¸£¸óÀÇ Àڱؿ¡ ÀÇÇØ ¼ºÀåÇÏ¸ç »ý¸®Àû ±â´ÉÀº Àß ¾Ë·ÁÁ® ÀÖÁö ¾ÊÀ½. ¼Õ¹ßÅé(nail) 2. ÁøÇÇ: Ç¥ÇÇ ¾Æ·¡¿¡ Á¸ÀçÇÏ´Â Á߹迱 ±â¿øÀÇ Á¶Á÷À¸·Î¼ Ç÷°ü, ¸²ÇÁ°ü, ½Å°æ, ±ÙÀ°, Ç¥ÇÇ ºÎ¼Ó±â µîÀ» Æ÷ÇÔÇϰí ÀÖÀ½. Ç¥ÇÇ ¹Ù·Î ¹ØÀÇ ºÎÀ§¸¦ À¯µÎ ÁøÇǶó ÇÏ°í ¾Æ·¡ÃþÀ» ¸Á»ó ÁøÇǶó ÇÑ´Ù. Á¶Á÷ ¼¶À¯¿¡´Â ¾Æ±³Áú ¼¶À¯, ±×¹° ¼¶À¯, ź·Â ¼¶À¯ÀÇ ¼¼ Á¾·ù°¡ ÀÖ´Ù. 3. ÇÇÇÏ Á¶Á÷: ÁøÇÇ ¾Æ·¡¿¡ Á¸ÀçÇϸç Á߹迱 ±â¿øÀ¸·Î¼ º¸¿Â ÀÛ¿ë, Ãæ°Ý Èí¼ö ÀÛ¿ë, ¿µ¾ç ÀúÀå ÀÛ¿ëÀÇ ±â´ÉÀÌ ÀÖ´Ù. |
||
| ¿µ¹® | skin dose | ÇÑ±Û | ÇǺμ±·® |
|---|---|---|---|
| ¼³¸í | 1. ÇǺÎÇ¥¸é¿¡¼ÀÇ ¹æ»ç¼±ÀÇ °øÁß¼±·®À¸·Î ¿©±â¿¡´Â 1Â÷¹æ»ç¼±°ú ÈĹæ»ê¶õÀÌ Æ÷ÇԵȴÙ. 2. ÇǺο¡ Èí¼öµÇ´Â ¼±·®. |
||
| SD | Sandhoff disease; senile dementia; septal defect; serologically defined; serologically detectable; s... |
|---|---|
| SSA | salicylsalicylic acid; sicca syndrome A; skin-sensitizing antibody; skin sympathetic activity; Sjogr... |
| ST | esotropia; scala tympani; scaphotrapezoid; sclerotherapy; sedimentation time; semitendinosus; sensor... |
| STD | selective T-cell defect; sexually transmitted disease; skin-to-tumor distance; skin test dose; sodiu... |
| MEN | Multiple Endocrine Neoplasia ; AD Trait 1. MEN Type I(= Wermer Syndro... |
| respiratory function tests | Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc. (12 Dec 1998) |
|---|---|
| personality tests | Standardised objective tests designed to facilitate the evaluation of personality. (12 Dec 1998) |
| microbial sensitivity tests | Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). (12 Dec 1998) |
| micronucleus tests | Induction and quantitative measurement of chromosomal damage leading to the formation of micronuclei in cells which have been exposed to genotoxic agents or ionizing radiation. (12 Dec 1998) |
| clinical chemistry tests | Laboratory tests demonstrating the presence of physiologically significant substances in the blood, urine, tissue, and body fluids with application to the diagnosis or therapy of disease. (12 Dec 1998) |
| placental function tests | Methods used for the assessment of placental function. (12 Dec 1998) |
| complement fixation tests | Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualised by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (haemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1. (12 Dec 1998) |
| word association tests | Lists of words to which individuals are asked to respond ascertaining the conceptual meaning held by the individual. (12 Dec 1998) |
| mutagenicity tests | Tests of chemical substances and physical agents for mutagenic potential. They include microbial, insect, mammalian cell, and whole animal tests. (12 Dec 1998) |
| haemagglutination inhibition tests | Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of haemagglutination. (12 Dec 1998) |
| haemagglutination tests | Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (12 Dec 1998) |
| haematologic tests | Tests used in the analysis of the hemic system. (12 Dec 1998) |
| precipitin tests | Serologic tests in which a positive reaction manifested by visible precipitation occurs when a soluble antigen reacts with its antibody. (12 Dec 1998) |
| predictive value of tests | In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. (12 Dec 1998) |
| pregnancy tests | Tests to determine whether or not an individual is pregnant. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|